Antikoagulační terapie u fibrilace síní
| Title in English | Anticoagulant therapy in atrial fibrillation |
|---|---|
| Authors | |
| Year of publication | 2011 |
| Type | Article in Periodical |
| Magazine / Source | Remedia |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | atrial fibrillation; warfarin; dabigatran; apixaban |
| Description | The trials with drugs intended to replace warfarin in patients with atrial fibrillation have been named by the American Heart Association among the top ten discoveries of the year 2010. These are the following trials: RE-LY, ROCKET AF, and AVERROES. The RE-LY trial showed dabigatran to be superior to warfarin in 18,113 patients, with dabigatran at a dose of 110 mg being equally effective against cerebrovascular events (CVE) as warfarin and dabigatran at a dose of 150 mg reducing CVE and not increasing bleeding events. The ROCKET AF trial showed a downward trend in CVE and systemic embolization in 14,246 patients treated with rivaroxaban versus warfarin, without increased bleeding risk. The AVERROES trial proved apixaban to be superior to acetyl salicylic acid (ASA) in patients with atrial fibrillation who were ineligible for warfarin therapy. Further large clinical trials such as ARISTOTLE and ENGAGE are underway and the Czech Republic is among the participating countries. |
| Related projects: |